Clinical Trial Update: Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

View source ↗

Summary

This clinical trial update describes a nonconforming expanded access protocol for lisocabtagene maraleucel (CAR-T therapy) and notes that it is available for pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Lymphoma, Large B-Cell, Diffuse | Status: AVAILABLE